MedTrace Logo

The Effects of Bifidobacterium Breve Bif195 for Small Intestinal Crohn's Disease

NCT04842149 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-05-30

No results posted yet for this study

Summary

The purpose of this study is to investigate if the probiotic Bifidobacterium breve Bif195 (Bif195) will result in improvement in clinical outcome in patients with small intestinal Crohn's disease.

Conditions

  • Crohn Disease

Interventions

DIETARY_SUPPLEMENT

Bif195 capsules

1 capsule daily for 8 weeks

DIETARY_SUPPLEMENT

Placebo capsules

1 capsule daily for 8 weeks

Sponsors & Collaborators

  • Chr Hansen

    collaborator INDUSTRY

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Andreas M Petersen, MD, PhD · Gastrounit, Copenhagen University Hospital Hvidovre, Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-21
Primary Completion
2024-04-30
Completion
2024-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04842149 on ClinicalTrials.gov